1. Raddeanin A Protects the BRB Through Inhibiting Inflammation and Apoptosis in the Retina of Alzheimer's Disease.
- Author
-
Wang, Xiao-Fang, Xiang, Xiao-Hong, Wei, Jing, Zhang, Peng-Bo, Xu, Qin, Liu, Meng-Han, Qu, Li-Qun, Wang, Xing-Xia, Yu, Lu, Wu, An-Guo, Qing, Da-Lian, Wu, Jian-Ming, Law, Betty Yuen-Kwan, Yu, Chong-Lin, and Yong-Tang
- Subjects
- *
ALZHEIMER'S disease , *CELL death , *RETINA , *INFLAMMATION , *PATHOLOGICAL physiology , *CATENINS , *APOPTOSIS - Abstract
Neuroinflammation and endothelial cell apoptosis are prominent features of blood–brain barrier (BBB) disruption, which have been described in Alzheimer's disease (AD) and can predict cognitive decline. Recent reports revealed vascular β-amyloid (Aβ) deposits, Muller cell degeneration and microglial dysfunction in the retina of AD patients. However, there has been no in-depth research on the roles of inflammation, retinal endothelial cell apoptosis, and blood-retinal barrier (BRB) damage in AD retinopathy. We found that Raddeanin A (RDA) could improve pathological and cognitive deficits in a mouse model of Alzheimer's disease by targeting β-amyloidosis, However, the effects of RDA on AD retinal function require further study. To clarify whether RDA inhibits inflammation and apoptosis and thus improves BRB function in AD-related retinopathy. In vitro we used Aβ-treated HRECs and MIO-M1 cells, and in vivo we used 3×Tg-AD mice to investigate the effect of RDA on BRB in AD-related retinopathy. We found that RDA could improve BRB function in AD-related retinopathy by inhibiting NLRP3-mediated inflammation and suppressing Wnt/β-catenin pathway-mediated apoptosis, which is expected to improve the pathological changes in AD-related retinopathy and the quality of life of AD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF